Stephen Freedland, MD

Articles by Stephen Freedland, MD

Final EMBARK Data Show “Almost Unprecedented” Reduction in Risk of Death With Enzalutamide Plus ADT in Biochemically Recurrent Prostate Cancer

October 19th 2025

Stephen Freedland, MD, highlighted data showing significant overall survival benefits in the EMBARK trial and discussed the continued role of monotherapy in preserving quality of life for select patients.

Latest Updated Articles

Trending on Pharmacy Times

Addressing Drug Resistance in Lung Cancer

From Mutation to Medicine: Targeted Therapies in Lung Cancer

Final EMBARK Data Show “Almost Unprecedented” Reduction in Risk of Death With Enzalutamide Plus ADT in Biochemically Recurrent Prostate Cancer

Five-Year NATALEE Data Show Ribociclib Improves Outcomes in High-Risk HR+/HER2– Early Breast Cancer

Abemaciclib Provides Long-Term Survival Benefit in High-Risk Early Breast Cancer